You can also stop by Booth 4284 anytime during the show. Noble Life Sciences has optimised an STZ-induced diabetes rat model. This is the model of choice for preclinical development of therapeutic ...

Pliant Therapeutics, a South San Francisco biotech company developing treatments for fibrosis, is slashing its staff after halting a crucial study over safety concerns. This layoff round arrives ...

Pliant Therapeutics announces a workforce reduction and cost-saving measures to extend its cash runway for late-stage clinical trials. Pliant Therapeutics, Inc. has announced a significant ...

SOUTH SAN FRANCISCO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced a strategic restructuring of its workforce and other cost saving actions to ...

He covers federal public health agencies. There were 26.4 deaths per 100,000 people from diabetes, according to early death certificate data for the third quarter of 2024 published this month by ...

European fintech Pliant has reportedly acquired the Austrian Insurtech hi.health. The acquisition enables Pliant to apply its payment expertise to the insurance sector while “gaining industry ...

Pliant Therapeutics, Inc., a clinical stage ... of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in ...

Mangoes may be linked to lower insulin resistance, a factor involved in the prevention of diabetes, a new study published in the journal Nutrients suggests. Researchers at the Illinois Institute ...

With Concentra Biosciences expanding its stock influence in Pliant Therapeutics and Acelyrin, the two biotechs have shored up their corporate defences against a potential acquisition. Both Pliant ...

Today, a brief rundown of news involving Acelyrin and Neumora Therapeutics, as well as updates from Biohaven, Lexicon Pharmaceuticals and Pliant Therapeutics you ... on the chronic nerve pain felt by ...

Pliant Therapeutics, Inc. announced the discontinuation of the BEACON-IPF Phase 2b trial assessing bexotegrast for patients with idiopathic pulmonary fibrosis due to safety concerns raised by an ...

Pliant plans to assess the full trial data and may explore lower doses in future Phase 2b studies. Ready to turn the market’s comeback into steady cash flow? Grab the top 3 stocks to buy right here.